Abstract 4520: Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early stage cancers: Evidences from glioma and colorectal carcinoma studies

2012 ◽  
Author(s):  
Sonya W. Song ◽  
Yuchen Li ◽  
Jing Zhang ◽  
Bin Zhang ◽  
Wei Yang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Colorectal Carcinoma ◽  
Early Stage ◽  
Binding Protein ◽  
Elevated Serum ◽  
Insulin Like Growth Factor ◽  
Serum Antibodies ◽  
Factor Binding

Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer

1995 ◽  
Vol 62 (3) ◽  
pp. 266-270 ◽  
Author(s):  
Peter F. Bruning ◽  
Jaap Van Doorn ◽  
Johannes M. G. Bonfrèr ◽  
Paul A. M. Van Noord ◽  
Catharina M. Korse ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Early Stage ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Factor Binding

scholarly journals Insulin-like growth factor-binding protein 7 (IGFBP7): Novel, independent marker of cardiometabolic diseases?

2019 ◽  
Vol 73 ◽  
pp. 735-740
Author(s):  
Anna Szyszkowska ◽  
Małgorzata Knapp ◽  
Karol Kamiński ◽  
Anna Lisowska
Keyword(s):  
Heart Failure ◽  
Cell Proliferation ◽  
Growth Factor ◽  
Ejection Fraction ◽  
Binding Protein ◽  
Elevated Serum ◽  
Acute Ischemia ◽  
Tubular Damage ◽  
Insulin Like Growth Factor ◽  
Factor Binding

Insulin-like growth factor-binding protein 7 (IGFBP7) is a 30kDa modular secreted protein involved in many physiologic processes, including cell proliferation, adhesion, senescence and angiogenesis. It is expressed in many organs and specific cells. It can interact with insulin-like growth factor 1(IGF-1), as well as with insulin. By binding to IGF-1, it limits IGF-1 access to IGF- receptor (IGF-R) and consequently neutralizes IGF-1 activity. Moreover, due to its high affinity to insulin, it may interfere with biological response of insulin and, therefore, it may be involved in the development of diabetes and cardiovascular diseases. According to research, it could be a good biomarker of heart failure. Its elevated serum concentrations were found in patients with heart failure, both with reduced ejection fraction and preserved ejection fraction. Moreover, IGFBP7 could be useful in predicting the presence of atherosclerotic lesions in coronary vessels, although its concentration does not reflect a degree of coronary artery disease (CAD) advancement and it cannot be used as a marker of acute ischemia. Its concentration is also associated with insulin resistance and the risk of metabolic syndrome. What is more, together with tissue inhibitor of metalloproteinases-2, it is a novel marker of tubular damage and it can be used for an early detection of acute kidney injury (AKI) endangered patients, which could allow for subsequent adjustments in medical therapy and the prevention of AKI. IGFBP7 is also regarded as a potential tumor suppressor in various cancers. Its low expression is potentially correlated with increased cancer cell proliferation.

Sign in / Sign up

Export Citation Format

Share Document